Skip to content
Oncology Research Hub

Miami, Florida

Cancer clinical trials in Miami, FL

200 cancer studies are recruiting participants at sites in Miami as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Miami at a glance

  • 200 studies are recruiting at a site in Miami.
  • By phase: Early Phase 1 (1), Phase 1 (21), Phase 1/2 (26), Phase 2 (54), Phase 2/3 (4), Phase 3 (53), Phase 4 (5), No phase (23), Observational (13). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (96), university, hospital or other (88), government (16).
  • By research area: Lymphoma (60), Breast Cancer (49), Lung Cancer (43), Prostate Cancer (24), Pancreatic Cancer (14), Melanoma (10).
  • Most recent update to one of these records: November 16, 2026.

Breast cancer studies recruiting in Miami

Basic details from each study's public record (the 30 most recently updated of 200). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    LeonaBio
    Study site
    Miami Cancer Institute
    Registry record
    NCT05696626 · updated
  2. A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    Miami Cancer Institute
    Registry record
    NCT07488676 · updated
  3. Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    UM Sylvester Comprehensive Cancer Center at Kendall · University of Miami Miller School of Medicine-Sylvester Cancer Center
    Registry record
    NCT03606967 · updated
  4. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    UM Sylvester Comprehensive Cancer Center at Kendall · University of Miami Miller School of Medicine-Sylvester Cancer Center
    Registry record
    NCT05564377 · updated
  5. A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

    • Phase 1
    • Ages 18 to 55
    • Female participants
    Sponsor
    TerSera Therapeutics LLC
    Study site
    Regis Clinical Research
    Registry record
    NCT07310420 · updated
  6. A Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients

    • Phase 4
    • Ages 18 and older
    • All sexes
    Sponsor
    Jonsson Comprehensive Cancer Center
    Study site
    University of Miami Health System
    Registry record
    NCT06934239 · updated
  7. ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    ALX Oncology Inc.
    Study site
    Sylvester Comprehensive Cancer Center
    Registry record
    NCT07007559 · updated
  8. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    • Phase 3
    • Ages 18 to 60
    • Female participants
    Sponsor
    NRG Oncology
    Study sites
    Miami Cancer Institute · UM Sylvester Comprehensive Cancer Center at Kendall · University of Miami Miller School of Medicine-Sylvester Cancer Center
    Registry record
    NCT05879926 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Miami, FL on ClinicalTrials.gov.

Lung cancer studies recruiting in Miami

  1. A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

    • Phase 3
    • Ages 18 to 100
    • All sexes
    Sponsor
    Amgen
    Study site
    Regis Clinical Research LLC
    Registry record
    NCT05920356 · updated
  2. Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University of Miami Miller School of Medicine-Sylvester Cancer Center
    Registry record
    NCT04665739 · updated
  3. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    UM Sylvester Comprehensive Cancer Center at Kendall · University of Miami Miller School of Medicine-Sylvester Cancer Center
    Registry record
    NCT06096844 · updated
  4. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Miami Cancer Institute
    Registry record
    NCT06498635 · updated
  5. Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.

    • No phase
    • Ages 50 to 80
    • All sexes
    Sponsor
    bioAffinity Technologies Inc.
    Study site
    Miami VA Healthcare System
    Registry record
    NCT07168993 · updated
  6. BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SystImmune Inc.
    Study site
    Total Health and Research Center
    Registry record
    NCT07625644 · updated
  7. A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    GlaxoSmithKline
    Study site
    GSK Investigational Site
    Registry record
    NCT07099898 · updated
  8. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Miami Cancer Institute at Baptist Health, Inc. ( Site 0214)
    Registry record
    NCT06623422 · updated
  9. A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Sylvester Comprehensive Cancer Center
    Registry record
    NCT06793215 · updated
  10. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Miami Cancer Institute at Baptist Health, Inc.
    Registry record
    NCT06119581 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Miami, FL on ClinicalTrials.gov.

Prostate cancer studies recruiting in Miami

  1. Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0051)
    Registry record
    NCT06136624 · updated
  2. Sacral Neuromodulation for Male Overactive Bladder (MOAB)

    • No phase
    • Ages 18 and older
    • Male participants
    Sponsor
    Axonics, Inc.
    Study site
    University of Miami
    Registry record
    NCT06511141 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Miami, FL on ClinicalTrials.gov.

Lymphoma studies recruiting in Miami

  1. Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Mount Sinai Comprehensive Cancer Center
    Registry record
    NCT06806033 · updated
  2. A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma

    • Phase 3
    • Ages 21 and older
    • All sexes
    Sponsor
    Aldeyra Therapeutics, Inc.
    Study site
    Bascom Palmer Eye Institute
    Registry record
    NCT07402876 · updated
  3. Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    UM Sylvester Comprehensive Cancer Center at Kendall · University of Miami Miller School of Medicine-Sylvester Cancer Center
    Registry record
    NCT04840602 · updated
  4. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Nicklaus Children's Hospital
    Registry record
    NCT05675410 · updated
  5. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    UM Sylvester Comprehensive Cancer Center at Kendall · University of Miami Miller School of Medicine-Sylvester Cancer Center
    Registry record
    NCT06337318 · updated
  6. Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Memorial Sloan Kettering Cancer Center
    Study site
    University of Miami
    Registry record
    NCT03618550 · updated
  7. A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    Nuvalent Inc.
    Study site
    University of Miami; Sylvester Cancer Center
    Registry record
    NCT05384626 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Miami, FL on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Miami

  1. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study site
    Investigative Site US075
    Registry record
    NCT07522073 · updated
  2. APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    UM Sylvester Comprehensive Cancer Center at Kendall · University of Miami Miller School of Medicine-Sylvester Cancer Center
    Registry record
    NCT04858334 · updated
  3. Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Immuneering Corporation
    Study site
    Miami Cancer Institute
    Registry record
    NCT07562152 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Miami, FL on ClinicalTrials.gov.

Ask about studies near Miami

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Florida

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call